Katharine Grimmer

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

Gerald S. Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau et al. · EClinicalMedicine · 2021 · 275 citations · Full text

Medicine, Oncology, Pharmacology +14

TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial

Rohit Loomba, Rizwana Mohseni, Kathryn Jean Lucas et al. · Gastroenterology · 2021 · 217 citations · Full text

Medicine, Internal Medicine, Pharmacology +11

Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4

Anan Chuntharapai, Kelly Dodge, Katharine Grimmer et al. · The Journal of Immunology · 2001 · 199 citations · Full text

Life Sciences, Oncology, Pharmacology +14

Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial

Rohit Loomba, Pierre Bédossa, Katharine Grimmer et al. · ˜The œLancet. Gastroenterology & hepatology · 2024 · 90 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Early phase collagen synthesis in lungs of rats exposed to bleomycin

Brent E. Van Hoozen, Katharine Grimmer, Gregory P. Marelich et al. · Toxicology · 2000 · 16 citations

Medicine, Biochemistry, Pharmacology +10